Marketing: Page 4
-
Sarah Silbiger via Getty Images
FDA, facing pressure, to review position on Zepbound, Mounjaro shortage
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in supply.
By Jonathan Gardner • Oct. 14, 2024 -
GSK’s ViiV to expand supply of HIV drug in Africa
The company is committing to make at least 2 million doses of its long-acting PrEP therapy available in low- and middle-income countries next year and in 2026.
By Delilah Alvarado • Oct. 7, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Permission granted by Gilead Sciences
Gilead agrees to license new HIV drug in low-income countries
The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease but limited resources.
By Delilah Alvarado • Oct. 2, 2024 -
Stock via Getty Images
Blue Shield of California sidesteps PBMs with new Humira biosimilar deal
It’s the first time, according to the insurer, that this type of model has been used to bring a Humira biosimilar to market, and it yields a much lower cost than both the brand-name version of the drug and biologic copycats.
By Rebecca Pifer • Oct. 2, 2024 -
iStock via Getty Images
How Roche plans to fill a projected $8B sales gap
Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.
By Amy Baxter • Oct. 2, 2024 -
Mario Tama via Getty Images
CVS to lay off 2,900 employees amid reports of strategic review
As CVS pursues a massive cost-cutting plan — and reportedly considers a potential breakup of its businesses — the healthcare behemoth has decided to cut 1% of its workforce.
By Rebecca Pifer • Oct. 1, 2024 -
Mario Tama via Getty Images
J&J drops 340B rebate plan after government pressure
Threatened with sanctions and loss of its agreement with Medicare and Medicaid, J&J is rolling back a plan to give hospitals after-the-fact rebates for 340B drugs.
By Rebecca Pifer • Oct. 1, 2024 -
Permission granted by Almac Clinical Services
Sponsored by Almac Clinical ServicesKey factors shaping the future of clinical services organizations in the APAC market
Clinical services organizations can help pharma with global drug development and clinical trial challenges.
Sept. 30, 2024 -
RiverNorthPhotography via Getty Images
Express Scripts sues FTC over report critical of PBM business practices
The pharmacy benefit manager said its lawsuit is necessary to protect against misinformation, while the FTC promised to defend its research.
By Rebecca Pifer • Sept. 17, 2024 -
Scott Olson via Getty Images
New research could ease concerns over suicide risk of obesity drugs
While results from two after-the-fact analyses were “reassuring,” outside experts urged “continued vigilance” to ensure GLP-1 drugs don’t worsen problems in people with preexisting mental health conditions.
By Jonathan Gardner • Sept. 3, 2024 -
Courtesy of Grail
Illumina avoids fine for Grail purchase in European court victory
The sequencing firm will avoid a penalty of 432 million euros after a court ruled the European Commission did not have jurisdiction to challenge the company’s Grail acquisition.
By Susan Kelly • Sept. 3, 2024 -
Getty Images Signature via Canva.com
Sponsored by StoryfulScript for success: The value of digital insights in pharma
Pharma companies can thrive in 2024 by leveraging digital intelligence to anticipate trends, analyze sentiment, and engage audiences. Discover how data-driven insights drive success.
Sept. 3, 2024 -
Drew Angerer via Getty Images
PBM executives threatened with fines for alleged perjury in House hearing
Testimony from the heads of Express Scripts, Optum Rx and Caremark in July defending pharmacy benefit managers’ business practices could be coming back to bite them.
By Rebecca Pifer • Aug. 29, 2024 -
Jeenah Moon via Getty Images
Pfizer launches DTC service for migraine, COVID drugs
The platform is similar in concept to a service launched this year by Eli Lilly, and aims to give consumers easier access to Pfizer’s migraine, COVID-19 and flu treatments.
By Delilah Alvarado • Aug. 27, 2024 -
JHVEPhoto via Getty Images
Lilly rolls out Zepbound vials at a discount price
The launch of a single-use vial form of the popular weight loss medicine could help Lilly improve supply and compete with telehealth companies offering compounded versions.
By Ned Pagliarulo • Aug. 27, 2024 -
Courtesy of Regeneron Pharmaceuticals
Regeneron gains European approval for bispecific lymphoma drug
Regulators in Europe granted approval based on remission rates, while the FDA sought more progress in confirmatory trials when it rejected Ordspono.
By Jonathan Gardner • Aug. 26, 2024 -
Alex Wong via Getty Images
Medicare drug price cuts could have limited early impact, but grow with time
Some in the industry described the level of price discounts announced by Medicare as a "relief," though they warned of larger implications for drug research in the future.
By Jonathan Gardner • Aug. 16, 2024 -
Permission granted by Incyte
Incyte builds out its arsenal of post-transplant drugs
The approval of Niktimvo in graft-versus-host disease hands Incyte another immune system-regulating medicine that analysts see as valuable, especially if use is broadened through additional clearances.
By Jacob Bell • Aug. 15, 2024 -
Courtesy of Madrigal Pharmaceuticals
Madrigal’s MASH drug launch gets off to a fast start
U.S. sales of the medicine, Rezdiffra, were more than triple analysts’ expectations, encouraging Madrigal to market it in Europe without a partner.
By Ben Fidler • Aug. 7, 2024 -
Permission granted by Moderna
RSV vaccine makers remain optimistic about market despite CDC guidance
An advisory committee’s age group recommendations could curtail wider use for now, but executives at GSK, Pfizer and Moderna still see plenty of upside.
By Michael Gibney • Aug. 6, 2024 -
Permission granted by Biogen
As sales climb, Biogen ‘convinced’ the worst is over for Leqembi
On a call with reporters, CEO Chris Viehbacher pointed to trends showing the Alzheimer’s drug is “on the right path” to becoming the lucrative product the company envisioned.
By Jacob Bell • Aug. 1, 2024 -
Courtesy of Merck & Co.
Merck shares slide as Gardasil sales drop in China
The unexpected disclosure in Merck’s second quarter earnings prompted an investor sell-off that some analysts said might be overblown.
By Kristin Jensen • July 31, 2024 -
Drew Angerer via Getty Images
Bristol Myers’ beat completes strong week of pharma earnings
All five large pharmaceutical companies that reported earnings last week raised either their profit or revenue guidance for the year.
By Ned Pagliarulo • July 26, 2024 -
Courtesy of Eisai
Leqembi voted down by European regulators
Eisai plans to appeal the EMA’s negative recommendation for the Alzheimer’s drug, hoping to break into a market analysts expect could eventually bring billions of dollars in sales.
By Jacob Bell • July 26, 2024 -
Permission granted by Boehringer Ingelheim
Boehringer cuts price of Humira biosimilar in bid to build use
The German drugmaker will offer a 92% discount on a copycat version of Humira for people who pay cash for the drug through GoodRx.
By Jonathan Gardner • July 18, 2024
Previous
